Program
ixoberogene soroparvovec
Also written as “6E11 vg/eye of ADVM-022”, “2E11 vg/eye of ADVM-022” and “ADVM-022”.
Its studies are mostly in Diabetic Retinopathy · Blindness, led by Eli Lilly.
Furthest: phase 2, since May 28, 20202 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 20 open or running | phase 2since May 28, 2020 | Nov 19, 2018 | none ahead |
- Named in Eli Lilly’s own pipeline as
Ixoberogene Soroparvovec (Ixo-Vec)
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2018First study: phase 1 study in BlindnessFirst studyNCT03748784 · 30 enrolled · United States
- May 28, 2020Phase 2 study in Diabetic RetinopathyNCT04418427 · 36 enrolled · United States, Puerto Rico
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04418427Diabetic Retinopathy · United States, Puerto Rico | 2 | Completed | Nov 22, 2022 | 36 |
| NCT03748784Blindness · United States | 1 | Completed | Jun 22, 2022 | 30 |
How it is read
Names in the registry
- “6E11 vg/eye of ADVM-022”, 1 entry
- “2E11 vg/eye of ADVM-022”, 1 entry
- “ADVM-022”, 1 entry
Conditions, from the studies’ own filings
- Diabetic Retinopathy, 1 study
- Blindness, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.